{
  "actions": [
    {
      "acted_at": "2011-06-22",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2011-06-22",
      "action_code": "H11100",
      "committees": [
        "HSJU"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the Committee on the Judiciary, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.",
      "type": "referral"
    },
    {
      "acted_at": "2011-06-22",
      "action_code": "H11100",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "text": "Referred to the Committee on the Judiciary, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.",
      "type": "referral"
    },
    {
      "acted_at": "2011-06-22",
      "action_code": "",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "text": "Referred to the Subcommittee on Health.",
      "type": "referral"
    },
    {
      "acted_at": "2011-08-25",
      "action_code": "",
      "committees": [
        "HSJU"
      ],
      "references": [],
      "text": "Referred to the Subcommittee on Intellectual Property, Competition and the Internet.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr2276-112",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "House Judiciary",
      "committee_id": "HSJU"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Judiciary",
      "committee_id": "HSJU",
      "subcommittee": "Subcommittee on Over-Criminalization Task Force",
      "subcommittee_id": "12"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF",
      "subcommittee": "Subcommittee on Health",
      "subcommittee_id": "14"
    }
  ],
  "congress": "112",
  "cosponsors": [],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2011-06-22",
  "number": "2276",
  "official_title": "To require the Director of the United States Patent and Trademark Office to conduct a study on effective ways to provide confirming genetic diagnostic test activity where gene patents and exclusive licensing exist, and for other purposes.",
  "popular_title": null,
  "related_bills": [
    {
      "bill_id": "hr1249-112",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    }
  ],
  "short_title": null,
  "sponsor": {
    "bioguide_id": "W000797",
    "district": "20",
    "name": "Wasserman Schultz, Debbie",
    "state": "FL",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2011-06-22",
  "subjects": [
    "Commerce",
    "Congressional oversight",
    "Genetics",
    "Government studies and investigations",
    "Health care costs and insurance",
    "Health care coverage and access",
    "Health care quality",
    "Intellectual property",
    "Medical tests and diagnostic methods"
  ],
  "subjects_top_term": "Commerce",
  "summary": {
    "as": "Introduced in House",
    "asOf": "2011-06-22",
    "date": "2011-08-11T16:14:11Z",
    "text": "Directs the Under Secretary of Commerce for Intellectual Property and Director of the U.S. Patent and Trademark Office (USPTO) to: (1) study ways to provide independent, confirming genetic diagnostic test activity where gene patents and exclusive licensing for primary genetic diagnostic tests exist; and (2) report the findings to Congress within nine months along with recommendations for establishing the availability of such independent confirming genetic diagnostic test activity.\n\nDefines \u0093confirming genetic diagnostic test activity\u0094 as the performance of a genetic diagnostic test, by a genetic diagnostic test provider, on an individual solely for the purpose of providing the individual with an independent confirmation of results obtained from another test provider\u0092s prior performance of the test on the individual."
  },
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To require the Director of the United States Patent and Trademark Office to conduct a study on effective ways to provide confirming genetic diagnostic test activity where gene patents and exclusive licensing exist, and for other purposes.",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To require the Director of the United States Patent and Trademark Office to conduct a study on effective ways to provide confirming genetic diagnostic test activity where gene patents and exclusive licensing exist, and for other purposes.",
      "type": "official"
    }
  ],
  "updated_at": "2019-11-15T21:34:59Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/112/hr/BILLSTATUS-112hr2276.xml"
}